Halozyme and Skye Bioscience Forge Collaboration to Tackle Obesity with Nimacimab

Partnership Overview

Halozyme Therapeutics, Inc. and Skye Bioscience, Inc. have announced a significant global collaboration aimed at innovating obesity treatment. This partnership, declared in January 2026, involves the licensing of Halozyme's proprietary ENHANZE® drug delivery technology by Skye for the development of a subcutaneous formulation of Nimacimab. The objective is to refine delivery methods to ensure enhanced efficiency in treating obesity—a therapeutic area that continues to expand.

Health Challenges of Obesity

Obesity is a growing global health crisis, affecting millions and leading to increased risks of chronic diseases such as diabetes, cardiovascular problems, and certain cancers. New treatment solutions are essential to combat this rising challenge effectively. The collaboration between Halozyme and Skye signals a strategic effort to support advances in obesity management through innovative drug delivery mechanisms.

ENHANZE® Technology

Halozyme’s ENHANZE® technology is designed to facilitate the subcutaneous administration of biologic therapies, reducing the treatment burden for patients. This approach allows for larger injection volumes, which can result in fewer shots and a more streamlined experience for those requiring long-term treatment. As highlighted by Halozyme’s CEO Dr. Helen Torley, this collaboration aims to explore the scalability of ENHANZE technology in various therapeutic applications, furthering efforts to drive sustainable growth through new partnerships.

Goals of the Collaboration

Punit Dhillon, Skye’s CEO, articulated a central goal of the partnership: to adequately evaluate the potential of Nimacimab by disposing of practical means to deliver higher doses subcutaneously. This includes exploring combination therapies alongside GLP-1 receptor agonists, a promising class of medications in managing obesity.

Halozyme is set to receive milestone payments aligned with product development advancements and a significant percentage of royalties from future sales derived from this collaborative effort over the next decade. The synergy of both companies capitalizes on technological expertise, focusing on improving patient outcomes in the evolving obesity market.

Future Trials and Research

Looking ahead, Skye has plans to initiate a Phase 2b clinical trial for Nimacimab using ENHANZE technology in mid-2026. This trial aims to rigorously assess the efficacy of the combination of Nimacimab with a GLP-1R agonist, which is anticipated to pave the way for potential regulatory approvals and commercial applications.

Conclusion

The collaboration between Halozyme and Skye represents a promising development in the fight against obesity. Through the innovative application of ENHANZE technology, both companies are poised to make strides in the pharmaceutical landscape. Enhanced subcutaneous drug delivery signifies a progressive approach to therapeutic interventions, ultimately hoping to reduce the global burden of obesity on healthcare systems worldwide.

As both companies move forward, the industry watches closely, optimistic about the potential of Nimacimab and the robust capabilities offered by ENHANZE to meet the demands of this critical public health challenge.